^ Clinical trial results posted on ClinicalTrials.gov, a website maintained by the NIH, were reviewed as of April 30, 2026. The 47 clinical trials evaluated subjective comfort as a primary or secondary endpoint for the ACUVUE^® OASYS Brand family (including daily disposable families), the 1-DAY ACUVUE^® MOIST Brand family (within the category of hydrogel daily disposable), and the ACUVUE^® VITA^® Brand family, vs. competitors’ products.

†Helps protect against transmission of harmful UV radiation to the cornea and into the eye. WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV- absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV- blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.

References:

1. JJV data on file 2024: ACUVUE^® Brand - EYE-INSPIRED^™ INNOVATIONS
2. Data on file 2024, ACUVUE^® Brand Contact Lenses for ASTIGMATISM overall fitting success, orientation position, rotational stability and vision performance.
3. JJV Data on File, 2022. CSM Subjective Responses ACUVUE^® OASYS MAX 1-Day Contact Lenses – Retrospective  Meta-analysis.